Celtrix's SomatoKine Offers Highest-Ever Doses Of IGF-1

4 August 1996

- Celtrix' SomatoKine (IGF-BP3 complex) is safe and delivers insulin-like growth factor-1 at higher dose levels than has ever been feasible before, according to the results of the firm's first Phase I study. IGF-1 is the active ingredient in Cephalon's Myotrophin (somatomedin C), which is nearing the market for the treatment of amyotrophic lateral sclerosis. Celtrix hopes to develop the drug, which is formulated along with its binding protein, for conditions such as major surgery, organ damage/failure after trauma, and severe osteoporosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight